Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
Rhea-AI Summary
Humacyte (Nasdaq: HUMA) announced that the Israel Ministry of Health accepted its Marketing Authorization Application for Symvess (acellular tissue engineered vessel) for arterial trauma repair and set a 180-working-day review period.
Acceptance references existing FDA approval for extremity vascular trauma and is described as a step in planned global expansion of Symvess.
Positive
- MAA acceptance by Israel Ministry of Health
- 180-working-day regulatory review period established
- Leverages FDA approval for extremity vascular trauma
- Progress toward global expansion of Symvess
Negative
- Regulatory decision remains pending after 180-working-day review
News Market Reaction – HUMA
In the Apr 21 session, HUMA declined 4.15%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Earnings and update | Positive | -13.2% | Reported 2025 results, Symvess sales, Saudi commitment and outlined key 2026 milestones. |
| Mar 26 | Leadership appointment | Positive | -5.4% | Named a new SVP of Business Development to drive collaborations and commercialization. |
| Mar 23 | Earnings date set | Neutral | +8.6% | Announced timing of Q4 and year-end 2025 results and business update webcast. |
| Mar 19 | Saudi commitment | Positive | -19.4% | Received binding $1.475M Symvess purchase commitment to support KSA evaluation program. |
| Mar 19 | Equity financing | Negative | -19.4% | Priced $20M registered direct stock offering to fund commercialization and pipeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent negative price reactions to operational and financing updates, even when the underlying news is positive or neutral, suggesting a tendency for the stock to sell off on good news and dilute-related events.
Over the last month, Humacyte has combined commercial progress with balance sheet actions. On Mar 19, it secured a $1.475M Symvess purchase commitment in Saudi Arabia but also priced a $20M registered direct offering, both followed by sharp declines. The Mar 27 earnings update highlighted modest 2025 revenue and upcoming Phase 3 and BLA milestones, yet the stock fell again. Today’s Israeli MAA acceptance continues the theme of expanding Symvess access outside the U.S. against a pressured share price.
Key Terms
marketing authorization application regulatory
maa regulatory
acellular tissue engineered vessel medical
vascular trauma medical
regenerative medicine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- The Ministry of Health has set a 180-working-day review period for the MAA -
- MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S -
DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that its Marketing Authorization Application (MAA) seeking approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair has been accepted by the Israel Ministry of Health. The Ministry of Health has set a 180-working-day review period for the MAA due to the existing Food and Drug Administration (FDA) approval of Symvess in extremity vascular trauma.
“We are very pleased that the Ministry of Health has accepted our MAA filing and has granted a 180-day review period,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “The MAA acceptance us another step in our planned global expansion of Symvess as we seek to provide this innovative regenerative medicine product to patients throughout the world. Many patients with severe vascular injuries are underserved by the current standard of care, and we are proud of the results that have been seen in our clinical trials and real-world humanitarian efforts.”.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
